| First Author | Hyslop SR | Year | 2020 |
| Journal | Oncogene | Volume | 39 |
| Issue | 29 | Pages | 5177-5186 |
| PubMed ID | 32535617 | Mgi Jnum | J:293693 |
| Mgi Id | MGI:6448276 | Doi | 10.1038/s41388-020-1357-6 |
| Citation | Hyslop SR, et al. (2020) Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma. Oncogene 39(29):5177-5186 |
| abstractText | Elevated platelet count is associated with poor survival in certain solid cancers, including lung cancer. In addition, experimental transplantation of cancer cell lines has uncovered a role for platelets in blood-borne metastasis. These studies, however, do not account for heterogeneity between lung cancer subtypes. Subsequently, the role of platelets in the major subtypes of non-small cell lung cancer (adenocarcinoma (ADC) and squamous cell carcinoma (SqCC)) is not fully understood. We utilised an autochthonous Kras(LSL-G12D/+);p53(flox/flox) mouse model of lung ADC together with genetic models of thrombocytopenia to interrogate the role of platelets in lung cancer growth and progression. While thrombocytopenia failed to impact primary tumour growth, in experimental metastatic models however, thrombocytopenic mice displayed significantly extended survival. Utilising a novel thrombocytopenic immunocompromised mouse, the importance of platelets in metastatic dissemination was confirmed with human KRAS-mutant ADC cell lines. Finally, retrospective analysis of a NSCLC patient cohort revealed thrombocytosis was predictive of poor survival in ADC patients with metastatic disease. Interestingly, this association was not apparent in SqCC patients. Overall, these data highlight the possibility of patient stratification using thrombocytosis as a biomarker, and indicates opportunities for potential novel treatment strategies that combine anti-platelet and lung cancer therapies. |
